Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study†

(2015) B. J. Monk et al.   ANNALS OF ONCOLOGY

Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study

(2014) S. Delaloge et al.   ANNALS OF ONCOLOGY

A preliminary Quality Control (QC) for next generation sequencing (NGS) library evaluation turns out to be a very useful tool for a rapid detection of BRCA1/2 deleterious mutations

(2014) Paola Concolino et al.   CLINICA CHIMICA ACTA

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

(2013) J. E. Ang et al.   CLINICAL CANCER RESEARCH

Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: A retrospective, multicenter study

(2013) Gabriella Ferrandina et al.   GYNECOLOGIC ONCOLOGY

Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials

(2013) José María del Campo et al.   MEDICAL ONCOLOGY

The Different Impact ofBRCAMutations on the Survival of Epithelial Ovarian Cancer Patients: A Retrospective Single-Center Experience

(2013) D. Lorusso et al.   ONCOLOGY

CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial

(2012) J Alexandre et al.   BRITISH JOURNAL OF CANCER

Impact of DNA polymorphisms in key DNA base excision repair proteins on cancer risk

(2012) B Karahalil et al.   HUMAN & EXPERIMENTAL TOXICOLOGY

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

(2012) Jonathan Ledermann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis

(2011) Claudia Lebedinsky et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas

(2011) Barbara Norquist et al.   JOURNAL OF CLINICAL ONCOLOGY

Trabectedin and Its C Subunit Modified Analogue PM01183 Attenuate Nucleotide Excision Repair and Show Activity toward Platinum-Resistant Cells

(2011) D. G. Soares et al.   MOLECULAR CANCER THERAPEUTICS

Integrated genomic analyses of ovarian carcinoma

(2011) D. Bell et al.   NATURE

A Review of Trabectedin (ET-743): A Unique Mechanism of Action

(2010) Maurizio D'Incalci et al.   MOLECULAR CANCER THERAPEUTICS

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment

(2009) Roisin O'Cearbhaill et al.   GYNECOLOGIC ONCOLOGY

Role of homologous recombination in trabectedin-induced DNA damage

(2008) M. Tavecchio et al.   EUROPEAN JOURNAL OF CANCER

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

“BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations

(2008) David S.P. Tan et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance to therapy caused by intragenic deletion in BRCA2

(2008) Stacey L. Edwards et al.   NATURE